SYNTHESIS & EVAL OF 1,5,6 TRIAZACHRYSENE & 5,6,11 TRIAZACHRYSENE DERIVATIVES

合成

• 批准号: 7721424
• 负责人: EDMOND J LAVOIE
• 金额: $ 0.57万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-02-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7721424
• 关键词: Binding; Camptothecin; Chemotherapy-Oncologic Procedure; Class; Clinic; Clinical; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Future; G-Quartets; Grant; Institution; Isoenzymes; Laboratories; Lead; Malignant Neoplasms; Pharmacologic Substance; Research; Research Personnel; Resources; Source; Topoisomerase II; Type I DNA Topoisomerases; United States National Institutes of Health; antitumor agent; chemotherapeutic agent; design; human TOP1 protein; improved; interest; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our primary research interests are in the discovery and the development of novel pharmaceuticals. For several years our research group has focused on the design and synthesis of novel non-camptothecin topoisomerase I-targeting antitumor agents. Several potent topoisomerase I-targeting agents have been identified. Studies are in progress to identify among these compounds the more promising candidates for development into the clinic. Recently, studies in our laboratory have been undertaken to develop agents that will selectively bind and stabilize G-quadruplex DNA. We are presently exploring the promise and full potential of these G-quadruplex stabilizers in cancer chemotherapy. In addition, our research group has initiated research into the discovery of new lead compounds for the development of isozyme specific topoisomerase II-targeting agents for the future development of an improved clinical agent within this class of cancer chemotherapeutic agents. See more at http://medchem.rutgers.edu/lavoie.shtml

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 我们的主要研究兴趣是新型药物的发现和开发。几年来，我们的研究小组一直集中在新型非膜片蛋白酶组酶I靶向抗肿瘤剂的设计和合成上。已经确定了几种有效的拓扑异构酶I靶向剂。正在进行研究以确定这些化合物中更有希望的候选人开发诊所的候选者。最近，我们在实验室进行了研究，以开发将有选择地结合和稳定G-四链体DNA的药物。目前，我们正在探索这些G四链体稳定剂在癌症化学疗法中的希望和全部潜力。此外，我们的研究小组还开始研究发现新的铅化合物，以开发同工酶特异性拓扑异构酶II靶向剂，以未来开发这类癌症化学治疗剂中改善的临床剂。 请参阅http://medchem.rutgers.edu/lavoie.shtml的更多信息